Uterine corpus leiomyoma
Therapeutic area
Rheumatology
Rare disease
No
- Definition
- A benign smooth muscle neoplasm arising from the body of the uterus. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Uterine corpus leiomyoma
- Therapeutic area
- Rheumatology
- uterine corpus leiomyoma
- body of uterus fibroid
- body of uterus leiomyoma
- corpus uteri fibroid
- corpus uteri leiomyoma
- fibroid of body of uterus
- fibroid of corpus uteri
- fibroid of the body of uterus
- fibroid of the corpus uteri
- fibroid of the uterine body
- fibroid of the uterine corpus
- fibroid of uterine body
- fibroid of uterine corpus
- leiomyoma of body of uterus
- leiomyoma of corpus uteri
- leiomyoma of the body of uterus
- leiomyoma of the corpus uteri
- leiomyoma of the uterine body
- leiomyoma of the uterine corpus
- leiomyoma of uterine body
- leiomyoma of uterine corpus
- uterine body fibroid
- uterine body leiomyoma
- uterine corpus fibroid
- uterine corpus leiomyomata
And 5 more, listed on the interactive page.
- Severity
- Mild
- Genetic
- Hereditary
Sources for recorded values
- Neuromuscular Disease
- Oncology
- Reproductive Health
- Rheumatology
Sources for recorded values
- MONDO ID
- MONDO:0007886
- Parent condition
- MONDO:0001572
Related records
Broader conditions (35)
- Benign female reproductive system neoplasm
- Benign muscle neoplasm
- Benign neoplasm
- Benign neoplasm of corpus uteri
- Benign reproductive system neoplasm
- Benign smooth muscle neoplasm
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Corpus uteri neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Female reproductive system disorder
- Female reproductive system neoplasm
- Fibroblastic neoplasm
- Fibroma
- Hereditary disease
- Hereditary disorder of connective tissue
Narrower conditions (11)
- Submucous uterine fibroid
- Subserous uterine fibroid
- Uterine corpus apoplectic leiomyoma
- Uterine corpus bizarre leiomyoma
- Uterine corpus cellular leiomyoma
- Uterine corpus diffuse leiomyomatosis
- Uterine corpus dissecting leiomyoma
- Uterine corpus epithelioid leiomyoma
- Uterine corpus lipoleiomyoma
- Uterine corpus myxoid leiomyoma
- Uterus interstitial leiomyoma
Trials (221)
- 4K Versus 3D Laparoscopic Colporraphy by Surgeons in Training: a Prospective Randomized Trial
- A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery
- A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids
- A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
- A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.
- A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects
- A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
- A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device
- A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
- A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (Ulipristal Acetate) as Pre-operative Treatment of Moderate to Severe Symptoms of Uterine Fibroids
- A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)
- A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma
- A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy
- A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
- A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
- a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.
- A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
- A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
- A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Approved drugs (2)
- Linzagolix choline
- Ulipristal acetate
Drugs in development (34)
- Acetylcysteine Phase 2
- Ascorbic acid Phase 3
- Asoprisnil Phase 3
- Carbetocin Phase 1
- Carboprost tromethamine Phase 1
- Cholecalciferol Phase 1
- Clomiphene citrate Phase 1
- Collagenase clostridium histolyticum Phase 1
- Curcumin Phase 3
- Dienogest Phase 2
- Dinoprostone Phase 3
- Elagolix Phase 3
- Epigalocatechin gallate Phase 3
- Estradiol Phase 3
- Goserelin Phase 3
- Letrozole Phase 1
- Leuprolide Phase 3
- Leuprolide acetate Phase 3
- Linzagolix Phase 3
- Mifepristone Phase 3
Other linked drugs (8)
- Epinephrine
- Ergonovine
- Gonadorelin
- Gonadorelin acetate
- Gonadorelin hydrochloride
- Terlipressin
- Tibolone
- Vasopressin